08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Celtura regulatory update

Novartis said its influenza A (H1N1) 2009 monovalent vaccines Celtura, Focetria and Fluvirin received prequalification from the World Health Organization (WHO) for use in national immunization programs, which makes vaccines available for purchase through United...
08:00 , Jan 4, 2010 |  BC Week In Review  |  Clinical News

Celtura: Phase I data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Celtura   Business: Infectious   Molecular target: Not applicable   Description: MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine   Indication: Vaccinate against swine influenza A (H1N1)...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Focetria: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 3.75 µg dose of Focetria met immune response criteria in children ages 3 to 8 at day 22. The trial enrolled 1,360...
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Focetria: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 7.5 µg dose of unadjuvanted swine influenza A (H1N1) vaccine met immune response criteria in adults and elderly subjects >=18 years old....
08:00 , Nov 23, 2009 |  BC Week In Review  |  Clinical News

Swine influenza A: Interim Phase II/III data

Interim data from an ongoing U.S. Phase II/III trial showed that a single 7.5 µg dose of unadjuvanted swine influenza A (H1N1) vaccine met immune response criteria in adults and elderly subjects >=18 aged years....
08:00 , Nov 9, 2009 |  BC Week In Review  |  Clinical News

Celtura regulatory update

Novartis said it received German marketing approval for Celtura, an MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine. The company said it is also pursuing approval of the vaccine in other countries, including Japan and...
02:26 , Nov 6, 2009 |  BC Extra  |  Company News

Germany approves Novartis' Celtura

Novartis AG (NYSE:NVS; SIX:NOVN) said the German regulatory authorities approved Celtura , an MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine. The pharma said it continues to pursue approval of the vaccine in other countries,...
07:00 , Sep 7, 2009 |  BC Week In Review  |  Clinical News

Celtura: Pilot trial data

Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   Product: Celtura   Business: Infectious   Molecular target: Not applicable   Description: MF59-adjuvanted cell culture-based swine influenza A (H1N1) vaccine   Indication: Vaccinate against swine influenza A (H1N1)...
00:14 , Sep 4, 2009 |  BC Extra  |  Clinical News

Novartis reports H1N1 vaccine data

Novartis AG (NYSE:NVS; SIX:NOVN) said data from a pilot trial in 100 healthy volunteers showed that Celtura induced hemagglutination-inhibition titers of at least 1:40 in 80% of subjects after one dose and more than 90%...